Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГБУЗ «Областная психиатрическая больница им. К.Р. Евграфова» 440026, г. Пенза, ул. Лермонтова, 28. skrembler@mail.ru
Список исп. литературыСкрыть список 1. Государственный реестр лекарственных средств [Электронный ресурс]. URL: http://grls.rosminzdrav.ru. (Дата обращения: 02.08.2023). / Gosudarstvennyj reestr lekarstvennyh sredstv [Elektronnyj resurs]. URL: http://grls.rosminzdrav.ru. (Data obrashcheniya: 02.08.2023). [in Russian]. 2. Peters L, Dyer M, Schroeder E et al. Invega Hafyera (Paliperidone Palmitate): Extended-Release Injectable Suspension for Patients With Schizophrenia. J Pharm Technol. 2023 Apr;39(2):88-94. 3. Пролонгированные нейролептики: между прошлым и будущим. В центре внимания. НЦПЗ РАМН. [Электронный ресурс]. URL: http://www.psychiatry.ru/stat/112. (Дата обращения: 02.08.2023). / Prolongirovanny`e nejroleptiki: mezhdu proshly`m i budushhim. V centre vnimaniya. NCzPZ RAMN. [Elektronnyj resurs]. URL: http://www.psychiatry. ru/stat/112. (Data obrashheniya: 02.08.2023). [in Russian]. 4. Stip E, Abdel-Baki A, Bloom D et al. Long-acting injectable antipsychotics: an expert opinion from the Association des médecins psychiatres du Québec. Can J Psychiatry. 2011 Jun;56(6):367-76. 5. Dencker, S.J., & Axelsson, R. (1996). Optimising the Use of Depot Antipsychotics. CNS Drugs, 6, 367-381. 6. Davis JM, Matalon L, Watanabe MD et al. Depot antipsychotic drugs. Place in therapy. Drugs. 1994 May;47(5):741-73. 7. López-Muñoz F, Alamo C, Cuenca E et al. History of the discovery and clinical introduction of chlorpromazine. Annals of Clinical Psychiatry. 2005 Jul-Sep. 17 (3): 113–35. 8. Kane JM, Aguglia E, Altamura AC et al. Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy. Eur Neuropsychopharmacol. 1998 Feb;8(1):55-66. 9. Johnson DA. Historical perspective on antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009 Nov;52:S7-12. 10. Gottfries CG, Green L. Flupenthixol decanoate in treatment of out-patients. Acta Psychiatr Scand Suppl. 1974;255:15-24. 11. Brissos S, Veguilla MR, Taylor D et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014 Oct;4(5):198-219. 12. Knudsen P. Chemotherapy with neuroleptics. Clinical and pharmacokinetic aspects with a particular view to depot preparations. Acta Psychiatr Scand Suppl. 1985;322:51-75. 13. Петрова Н.Н. Антипсихотики пролонгированного действия: традиции и инновации. Психиатрия, психотерапия и клиническая психология. № 4 (22), 2015, С.121-134. 14. Naber, D. (2011). Olanzapine pamoate for the treatment of schizophrenia. Expert Opinion on Pharmacotherapy, 12, 627 — 633. 15. Currier G, Walsh P. Safety and efficacy review of inhaled loxapine for treatment of agitation. Clin Schizophr Relat Psychoses. 2013 Apr;7(1):25-32. 16. Rabin C, Liang Y, Ehrlichman RS et al. In vitro and in vivo demonstration of risperidone implants in mice. Schizophr Res. 2008 Jan;98(1-3):66-78. 17. Sieberns S, Spechtmeyer H. cis(Z)-Clopenthixol decanoate a new depot neuroleptic. Int Pharmacopsychiatry. 1982;17(3):170-84. 18. Free U.S. Outpatient Drug Usage Statistics [Electronic resource]. ClinCalc DrugStats Database. URL: http://clincalc.com/DrugStats/. (access date: 02.08.2023). 19. Glazer WM. Who receives long-acting antipsychotic medications? Psychiatr Serv. 2007 Apr;58(4):437. 20. Byerly M., Fisher R., Rush A.J. et al. Comparison of clinician vs electronic monitoring of antipsychotic adherence in schizophrenia (poster). Presented at the 41st annualmeeting of the American College of Neuropsychopharmacology. San Juan, Puerto Rico. 2000, Dec. 10. 21. Tiihonen J, Mittendorfer-Rutz E, Majak M et al. Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients with Schizophrenia. JAMA Psychiatry. 2017;74:686-693. 22. Pacchiarotti I, Tiihonen J, Kotzalidis GD et al. Long-acting injectable antipsychotics (LAIs) for maintenance treatment of bipolar and schizoaffective disorders: A systematic review. Eur Neuropsychopharmacol. 2019 Apr;29(4):457-470. 23. Samalin L, Nourry A, Charpeaud T et al. What is the evidence for the use of second-generation antipsychotic long-acting injectables as maintenance treatment in bipolar disorder? Nord J Psychiatry. 2014 May;68(4):227-35. 24. Gigante AD, Lafer B, Yatham LN. Long-acting injectable antipsychotics for the maintenance treatment of bipolar disorder. CNS Drugs. 2012 May 1;26(5):403-20. 25. Marcus SC, Zummo J, Pettit AR et al. Antipsychotic Adherence and Rehospitalization in Schizophrenia Patients Receiving Oral Versus Long-Acting Injectable Antipsychotics Following Hospital Discharge. J Manag Care Spec Pharm. 2015 Sep;21(9):754-68. 26. Huang CY, Fang SC, Shao YJ. Comparison of Long-Acting Injectable Antipsychotics With Oral Antipsychotics and Suicide and All-Cause Mortality in Patients With Newly Diagnosed Schizophrenia. JAMA Netw Open. 2021 May 3;4(5):e218810. 27. Kishimoto T, Hagi K, Kurokawa S et al. Long-acting injectable versus oral antipsychotics for the maintenance treatment of schizophrenia: a systematic review and comparative meta-analysis of randomised, cohort, and pre-post studies. Lancet Psychiatry. 2021 May;8(5):387-404. 28. Lin D, Thompson-Leduc P, Ghelerter I et al. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis. CNS Drugs. 2021 May;35(5):469-481. 29. Barnes TR, Curson DA. Long-term depot antipsychotics: a risk-benefit assessment. Drug Saf 1994; 10: 464–79. 30. Kane JM, Davis JM, Schooler N et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002; 159: 554–60. 31. Marder SR, Midha KK, Van Putten T et al. Plasma levels of fluphenazine in patients receiving fluphenazine decanoate: relationship to clinical response. Br J Psychiatry 1991; 158: 658–65. 32. Midha KK, Hubbard JW, Marder SR et al. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia. J Psychiatry Neurosci 1994; 19: 254–64. 33. Nayak RK, Doose DR, Nair NP. The bioavailability and pharmacokinetics of oral and depot intramuscular haloperidol in schizophrenic patients. J Clin Pharmacol 1987; 27: 144–50. 34. Мосолов С.Н., Калинин В.В., Еремин А.В. Cравнительная эффективность и пере¬носимость нового поколения антипсихотических средств при лечении обострений шизофрении (мета-анализ оригинальных исследований оланзапина, рисперидона, кветиапина, клозапина и галоперидола]. // Новые достижения в терапии психиче¬ских заболеваний / Под ред. С.Н. Мосолова. - М., 2002. С. 82-94. 35. Atkins M, Burgess A, Bottomley C et al. Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications. Psychiatric Bulletin. 1997 Apr, 21(4): 224-226. 36. Филилеева О.В., Мосолов С.Н. Эквивалентные дозировки антипсихотических препаратов. Современная терапия психических расстройств. 2019. №3. С. 36-44. / Filileeva O.V., Mosolov S.N. E`kvivalentny`e dozirovki antipsixoticheskix preparatov. Sovremennaya terapiya psixicheskix rasstrojstv. 2019. №3. S. 36-44. [in Russian]. 37. Danivas V, Venkatasubramanian G. Current perspectives on chlorpromazine equivalents: Comparing apples and oranges! Indian J Psychiatry. 2013 Apr-Jun. 55(2): 207–208. 38. Рабочая группа РОП. 2019. Клинические рекомендации по диагностике и лечению психических и поведенческих расстройств. Проект клинических рекомендаций "Шизофрения (F20)". Сайт Российского общества психиатров. [Электронный ресурс]. URL: http://psychiatr.ru/ download/4244?view=1&name=КР_+Шизофрения_25-11.pdf (дата обращения: 02.08.2023) / Rabochaya gruppa ROP. 2019. Klinicheskie rekomendacii po diagnostike i lecheniyu psixicheskix i povedencheskix rasstrojstv. Proekt klinicheskix rekomendacij "Shizofreniya (F20)". Sajt Rossijskogo obshhestva psixiatrov. [E`lektronny`j resurs]. URL: http://psychiatr. ru/download/4244?view=1&name=КР_+Шизофрения_25-11.pdf (Data obrashheniya: 02.08.2023). [in Russian]. 39. Jann MW, Ereshefsky L, Saklad SR. Clinical pharmacokinetics of the depot antipsychotics. Clin Pharmacokinet. 1985 Jul-Aug;10(4):315-33. 40. Jrgensen A, Overø KF. Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels. Acta Psychiatr Scand Suppl. 1980;279:41-54. 41. Romero Guillena S.L. Paliperidone palmitate vs conventional depot antipsychotics. Poster presented at EPA Congress, Munich. 2014. March 1–4. 42. Оленева Е.В., Рывкин П.В., Ладыженский М.Я. Возможности палиперидона пальмитата в длительной противорецидивной терапии шизофрении (обзор доказательных исследований). Современная терапия психических расстройств. 2018. – № 1. – С. 37:44. 43. Cameron C, Zummo J, Desai DN et al. Aripiprazole Lauroxil Compared with Paliperidone Palmitate in Patients with Schizophrenia: An Indirect Treatment Comparison. Value Health. 2017;20(7):876-885. 44. Correll CU, Kim E, Sliwa JK et al. Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview. CNS Drugs. 2021 Jan;35(1):39-59.